A system that combines magnetic resonance imaging guidance with high-intensity focused ultrasound to noninvasively treat pain in cancer patients with bone metastases.
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
Elvitegravir (Formerly GS-9137)
An oral integrase inhibitor for the treatment of human immunodeficiency virus infection.
Jetrea® (Ocriplasmin Intravitreal Injection)
Recombinant human microplasmin intravitreal injection for treatment of symptomatic vitreomacular adhesion, including macular hole.
CytoSorb® Blood Filtration Device
A hemoperfusion blood filtration device under investigation for use as an adjunct to current care treatments in patients who develop severe sepsis in the critical care setting.
Solitaire™ Flow Restoration (FR) Intra-Arterial Thrombectomy Device
A fully retrievable, self-expanding, intracranial stent for acute revascularization of large vessel occlusions in patients with ischemic stroke who are ineligible for or who fail intravenous tissue plasminogen activator therapy.
S-ICD® (Subcutaneous Implantable Cardioverter Defibrillator)
An entirely subcutaneous implantable cardioverter defibrillator that does not use transvenous lead wires, proposed to detect and correct life-threatening arrhythmias in selected patients at risk of sudden cardiac death.
Eylea® (Aflibercept Intravitreal Injection, Formerly VEGF Trap-Eye) for Age-Related Macular Degeneration
A recombinant fusion protein for intravitreal injection to treat the wet form of age-related macular degeneration.
Eylea® (Aflibercept Intravitreal Injection, Formerly VEGF Trap-Eye) for Macular Edema Following Central Retinal Vein Occlusion
A recombinant fusion protein for intravitreal injection to treat macular edema following central retinal vein occlusion.
Aubagio® (Teriflunomide)
A once-daily oral therapy for the treatment of relapsing remitting multiple sclerosis.
Xtandi® (Enzalutamide, Formerly MDV3100)
A once-daily, oral, hormonal treatment for metastatic, castration-resistant, prostate cancer in men who have previously received docetaxel.